Review Committee on Genetic Manipulation (RCGM)

The Review Committee on Genetic Manipulation (RCGM) is a statutory regulatory body constituted under the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989 (commonly called the "Rules 1989"), notified by the Ministry of Environment, Forest and Climate Change under Sections 6, 8 and 25 of the Environment (Protection) Act, 1986. The Rules 1989 establish a multi-tier architecture for governing modern biotechnology in India, and the RCGM occupies the central operational tier. Unlike the apex Genetic Engineering Appraisal Committee (GEAC), which sits within the environment ministry, the RCGM is functionally housed within and serviced by the Department of Biotechnology (DBT) under the Ministry of Science and Technology. Its creation reflected the policy judgment that ongoing scientific oversight of recombinant DNA work required a body anchored in scientific administration rather than in the environmental clearance machinery alone.

Procedurally, the RCGM functions as the body that monitors all ongoing research activities involving genetically modified organisms (GMOs) and products derived from recombinant DNA technology. A researcher or institution wishing to undertake such work must first secure clearance from the institution-level Institutional Biosafety Committee (IBSC), which is the base tier of the 1989 framework. The IBSC forwards proposals involving higher-risk categories or whole-organism work to the RCGM, which reviews them for biosafety, containment adequacy, and conformity with the prescribed risk categories. The RCGM issues guidelines for laboratory and greenhouse containment, sanctions the import and export of genetically engineered cells and organisms for research purposes, and authorises the generation of biosafety data. Critically, it grants approval for confined or small-scale field trials—the Biosafety Research Level-I (BRL-I) and limited multi-location trials—generating the data later evaluated by the GEAC for any large-scale environmental release.

Beyond approval of individual proposals, the RCGM performs a continuous monitoring function. It establishes review procedures, lays down protocols for the safe conduct of research, and may appoint Monitoring-cum-Evaluation Committees (MECs) to visit experimental field sites, inspect containment, and verify that trial conditions match the sanctioned protocol. The committee also clears the import of transgenic plant material, seeds, and genetic constructs for laboratory study. Its membership is drawn from the DBT, the Indian Council of Medical Research, the Indian Council of Agricultural Research, the Council of Scientific and Industrial Research, and other relevant scientific institutions, giving it cross-domain expertise spanning agriculture, health, and industrial biotechnology. Once research generates sufficient biosafety information, the RCGM transmits the dossier upward to the GEAC, which holds the sole authority to approve commercial release and large-scale use.

In practice, the RCGM has been central to several landmark cases. It oversaw the early-stage research and confined trials of Bt cotton before the GEAC's commercial approval in 2002, and it has processed proposals for Bt brinjal, whose commercial release the environment ministry placed under an indefinite moratorium in February 2010 despite a favourable GEAC recommendation in 2009. The committee has also reviewed transgenic mustard (DMH-11) developed by the Centre for Genetic Manipulation of Crop Plants at the University of Delhi, COVID-19 vaccine candidates employing recombinant platforms during 2020–2021, and numerous gene-therapy and industrial-enzyme proposals routed through the DBT. Its decisions are documented in published guidelines such as the 1990 Recombinant DNA Safety Guidelines and successive revisions issued jointly with the DBT.

The RCGM must be distinguished from the adjacent bodies in the same regulatory chain. The GEAC is the apex appraisal and approval authority for environmental release, commercialisation, and large-scale use; the RCGM, by contrast, handles the research and confined-trial stages and cannot authorise commercial cultivation or marketing. The IBSC operates below the RCGM at the institutional level and handles routine, lower-risk work. The State Biotechnology Coordination Committees (SBCC) and District Level Committees (DLC) sit alongside this structure as enforcement and inspection bodies at the sub-national level. Confusing the RCGM with the GEAC is a recurring error in policy commentary: the RCGM clears the science and the data generation, while the GEAC decides whether a product reaches farmers and consumers.

The framework has attracted sustained controversy and reform proposals. Critics argue that locating the RCGM within the DBT—a body simultaneously charged with promoting biotechnology—creates a conflict between promotion and regulation, an issue raised repeatedly during the Bt brinjal debate and in parliamentary committee reports. The proposed Biotechnology Regulatory Authority of India (BRAI) Bill, introduced in 2013, sought to consolidate the RCGM, GEAC and allied bodies into a single independent statutory regulator; the bill lapsed and was not enacted. Litigation before the Supreme Court of India, including the long-running Aruna Rodrigues writ petition and the Technical Expert Committee constituted by the Court, scrutinised the adequacy of RCGM-level field-trial oversight and recommended stronger conflict-of-interest safeguards. The 2022 GEAC clearance of GM mustard for environmental release, following years of RCGM-stage trials, revived these debates.

For the working practitioner—a UPSC aspirant addressing General Studies Paper III, a desk officer in the agriculture or science ministries, or an analyst tracking biosafety governance—the RCGM is the pivot of India's GMO regulatory architecture. Understanding that biosafety data originates at the IBSC and RCGM tiers, and that the GEAC's high-profile clearances rest on that prior groundwork, is essential to assessing both the rigour and the institutional vulnerabilities of the system. The committee illustrates how India operationalises the Cartagena Protocol on Biosafety obligations domestically, and it remains the body whose technical assessments determine whether a transgenic crop or therapeutic ever advances toward release.